HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CFSAN Should Prioritize Reminding CDER Of Supplement Jurisdiction – AHPA

This article was originally published in The Tan Sheet

Executive Summary

FDA's food center should assert its jurisdiction over dietary supplement labeling with the agency's drug center, the American Herbal Products Association says in comments on the Center for Food Safety and Applied Nutrition's fiscal 2008 priorities

You may also be interested in...



AHPA Asks FDA To Allow Firms To Route AER Contact To Offices Outside U.S.

FDA's guidance on adverse event reporting for OTC drugs and dietary supplements should assure that firms operating outside the country can use U.S. addresses on their product labels but receive AER-related communication in their home countries, the American Herbal Products Association recommends

CFSAN Seeks Recommendations On Fiscal 2008 Priorities

FDA's Center for Food Safety and Applied Nutrition is seeking comments on its fiscal 2008 priorities as it starts the final quarter of a year in which it achieved multiple significant goals

Supplement GMPs Stress Responsibility, Put Firms In Driver’s Seat For Testing

The dietary supplement good manufacturing practices final rule provides "a very flexible framework for required testing," said Vasilios H. Frankos, director of the dietary supplement programs division for FDA's Center for Food Safety and Applied Nutrition

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS138557

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel